Skip to main content
. 2024 Oct 14:15910199241289628. Online ahead of print. doi: 10.1177/15910199241289628

Table 1.

Baseline characteristics.

Author Year Data collection Country Age (years), median (IQR) OR mean (SD) Gender, N (%) NIHSS score at baseline, median (IQR) OR mean (SD) Population (N) Preoperative D-dimer, median (IQR) OR mean (SD) EVT Outcome of interest
Total Technique Successful reperfusion Favorable outcome
Definition N Definition N
Aoki et al. 11 2020 R Japan sMR: 82 (76–86); nsMR: 77 (71–83) M = 72 (56.69) sMR: 18 (13–24); nsMR: 19 (12–24) 127 sMR: 2.0 (1.1–3.4); nsMR: 1.6 (0.9–3.3) 127 Aspiration & Stent TICI 3 53 mRS 0–2 32 Functional outcome
Baek et al. 12 2023 R Republic of Korea 71.3 (±12.9) M = 113 (52.6) 14.0 (9.0–19.0) 215 757.0 (392.0–2562.5) ng/mL 215 Aspiration & Stent mTICI ≥ 2b-3 203; FPE (mTICI 2c-3): 71 mRS 0–2 87 Successful reperfusion, FPE, and functional outcome
Han et al. 13 2023 R China 67.08 ± 11.67 F = 87 (36) 14 (11, 19) 245 1.28 (0.7, 2.61) mg/L 245 Aspiration - - mRS 0–2 122 Deep venous thrombosis
Hisamitsu et al. 14 2022 R Japan 74.75 (±11.11) M = 43 (49.4) 15.51 (±5.95) 87 Favorable outcome: 1.74 (2.02); Unfavorable: 3.33 (3.16) µg/mL 87 Aspiration & Stent mTICI ≥ 2b-3 80 mRS 0–2 47 Functional outcome
Lee et al. 15 2021 R Republic of Korea 68.46 ± 13.2 M = 178 (52.2) CRS: 18 (11–23); Control: 15 (8–19) 341 Favorable outcome: 10.7 (6.66–17.71); Unfavorable: 16.95 (14.55–26.60) 341 Aspiration & Stent mTICI ≥ 2b-3 295 mRS 0–2 CRS: 11/34 Functional outcome
Li W. et al. 18 2020 R China Reocclusion: 57.3 (±10.3); Non-reocclusion: 63.6 (±12.4) M = 464 (75.57) Occlusion: 15 (12–20); Non-reocclusion: 16 (12–23) 614 Reocclusion: 2 (0.8–4.7); Non-reocclusion: 0.8 (0.4–1.9) mmol/L 614 Stent mTICI ≥ 2b-3 - mRS 0–2 230 Re-occlusion rate
Li J. et al. 16 2023 R China 63.6 ± 12.6 F = 104 (30.3) 15.2 ± 4.5 343 1.3 (0.7–3.1) 343 Aspiration & Stent mTICI ≥ 2b-3 259 mRS <2 162 Functional outcome
Li L. et al. 17 2023 R China Validation = favorable: 67 (59–71); unfavorable: 66 (59–70); Test = favorable: 54.5 (32–71.5); unfavorable: 61 (55.5–76) M = 64 Validation = favorable: 12 (9–15); unfavorable: 15 (13–18); Test = favorable: 14 (10.25–15.75); unfavorable: 13 (11–15) 102 Validation = favorable: 0.96 (0.59–2.24); unfavorable: 2.60 (0.92–190); Test = favorable: 1.00 (0.75–2.52); unfavorable: 0.59 (0.55–7.54) 102 NR mTICI ≥ 2b-3 93 mRS 0–2 46 Functional outcome
Mitsuhashi et al. 19 2023 R Japan 85 (83–87) F = 27 (61.02) 24 (18–27) 59 Favorable: 1.25 (1.2–4.05); Unfavorable: 2 (0.875–1.8)  µg/mL 59 Aspiration & Stent mTICI ≥ 2b-3 44 mRS 0–3 28 Functional outcome
Ohbuchi et al. 20 2022 R Japan 76 ± 12 F = 49 (40) 18 ± 8 121 4.4 ± 6.6 µg/mL 121 Aspiration & Stent mTICI ≥ 2b-3 88 mRS 0–3 39 Functional outcome and successful reperfusion
Pan et al. 21 2022 P South Korea 65.59 M = 36 (52.9) 15 (10–20) 68 16.07 μg/mL 36 Aspiration & Stent mTICI ≥ 2b-3 20 mRS 0–2 18 Functional outcome and successful reperfusion
Qiu et al. 22 2022 R China 69.7 ± 12.7 M = 207 (52.4) 16 (12–21) 395 0.87 (0.42–1.83)  mg/L 395 Aspiration & Stent mTICI ≥ 2b-3 328 - - sICH
Song et al. 23 2020 R Republic of Korea FPE: 69.6 (13.5); non-FPE: 68.0 (13.9) M = 133 (55.88) FPE: 10 (3–17); non-FPE: 9 (2–18) 238 FPE: 4 (3.86); non-FPE: 4.01 (3.75) mg/L 238 Stent mTICI ≥ 2b-3 228 mRS 0–2 141 FPE
Xie and Tang 24 2023 R China 69.5 ± 12.9 M = 163 (52.1) 15 (12–21) 313 0.85 (0.40–1.76)  mg/L 313 Aspiration & Stent mTICI ≥ 2b-3 254 mRS 0–2 111 FPE

R: retrospective; P: prospective; M: male; F: female; sMR and nsMR: significant and non-significant mitral regurge; CRS: cancer-related stroke; FPE: first-pass effect; NR: not reported; mTICI: modified thrombolysis in cerebral infarction; sICH; symptomatic intracranial hemorrhage; mRS: modified Rankin scale; NIHSS: National Institute of Health Stroke Scale; DVT: deep venous thrombosis.